OBJECTIVES: Nasopharyngeal carcinoma (NPC) is a rare cancer in the United States. An association between NPC and Epstein-Barr virus (EBV) is well-established for World Health Organization (WHO) types II and III (WHO-II/III) NPC but less well-established for WHO type I (WHO-I) NPC. Given the rise in oropharyngeal tumors positive for high-risk human papillomavirus (HPV) and the unique biology of WHO-I NPC, we examined the relationship between HPV and WHO-I NPC. STUDY DESIGN: Retrospective case-comparison study. METHODS: A search of a large multidisciplinary cancer center tumor registry identified 183 patients seen from January 1999 to December 2008 with incident NPC and no prior cancer. Available paraffin-embedded tumor specimens (N = 30) were analyzed for oncogenic HPV status by in situ hybridization (ISH) and polymerase chain reaction (PCR) for HPV-16 and HPV-18; EBV status by ISH; and p16 expression by immunohistochemistry. Demographic parameters, including race and smoking, were obtained from the medical records. RESULTS: Among the 18 WHO-I NPC patients, 66% (N = 12) were smokers and 17% (N = 3) Asian; among the 165 WHO-II/III NPC patients, 44% (N = 73) were smokers and 24% (N = 39) Asian. Eight WHO-I NPC patients had available paraffin blocks; five of six were HPV-16-positive by PCR and four of eight were HPV-positive by ISH; only two of eight (25%) were EBV-positive. Twenty-two WHO-II/III NPC patients had available paraffin blocks; only 1 was HPV-positive by ISH, and 13 of 22 (60%) were EBV-positive. CONCLUSIONS: These results suggest that WHO-I NPC is associated with oncogenic HPV, although larger studies are needed to verify these findings. Laryngoscope, 2010.
OBJECTIVES:Nasopharyngeal carcinoma (NPC) is a rare cancer in the United States. An association between NPC and Epstein-Barr virus (EBV) is well-established for World Health Organization (WHO) types II and III (WHO-II/III) NPC but less well-established for WHO type I (WHO-I) NPC. Given the rise in oropharyngeal tumors positive for high-risk human papillomavirus (HPV) and the unique biology of WHO-I NPC, we examined the relationship between HPV and WHO-I NPC. STUDY DESIGN: Retrospective case-comparison study. METHODS: A search of a large multidisciplinary cancer center tumor registry identified 183 patients seen from January 1999 to December 2008 with incident NPC and no prior cancer. Available paraffin-embedded tumor specimens (N = 30) were analyzed for oncogenic HPV status by in situ hybridization (ISH) and polymerase chain reaction (PCR) for HPV-16 and HPV-18; EBV status by ISH; and p16 expression by immunohistochemistry. Demographic parameters, including race and smoking, were obtained from the medical records. RESULTS: Among the 18 WHO-I NPC patients, 66% (N = 12) were smokers and 17% (N = 3) Asian; among the 165 WHO-II/III NPC patients, 44% (N = 73) were smokers and 24% (N = 39) Asian. Eight WHO-I NPC patients had available paraffin blocks; five of six were HPV-16-positive by PCR and four of eight were HPV-positive by ISH; only two of eight (25%) were EBV-positive. Twenty-two WHO-II/III NPC patients had available paraffin blocks; only 1 was HPV-positive by ISH, and 13 of 22 (60%) were EBV-positive. CONCLUSIONS: These results suggest that WHO-I NPC is associated with oncogenic HPV, although larger studies are needed to verify these findings. Laryngoscope, 2010.
Authors: C H Rassekh; P L Rady; I Arany; S K Tyring; S Knudsen; K H Calhoun; H Seikaly; B J Bailey Journal: Laryngoscope Date: 1998-03 Impact factor: 3.325
Authors: Jens P Klussmann; Elif Gültekin; Soenke J Weissenborn; Ulrike Wieland; Volker Dries; Hans P Dienes; Hans E Eckel; Herbert J Pfister; Pawel G Fuchs Journal: Am J Pathol Date: 2003-03 Impact factor: 4.307
Authors: T L Vaughan; J A Shapiro; R D Burt; G M Swanson; M Berwick; C F Lynch; J L Lyon Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-08 Impact factor: 4.254
Authors: G Della Torre; S Pilotti; R Donghi; G Pasquini; A Longoni; C Grandi; P Salvatori; M A Pierotti; F Rilke Journal: Diagn Mol Pathol Date: 1994-03
Authors: A Giannoudis; M Ergazaki; J Segas; J Giotakis; G Adamopoulos; V Gorgoulis; D A Spandidos Journal: Cancer Lett Date: 1995-03-02 Impact factor: 8.679
Authors: Heather M Walline; Chris Komarck; Jonathan B McHugh; Serena A Byrd; Matthew E Spector; Samantha J Hauff; Martin P Graham; Emily Bellile; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Douglas B Chepeha; Francis P Worden; Matthew H Stenmark; Avraham Eisbruch; Carol R Bradford; Thomas E Carey Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-12 Impact factor: 6.223
Authors: Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: Zhixiong Lin; Brian Khong; Shirley Kwok; Hongbin Cao; Robert B West; Quynh-Thu Le; Christina S Kong Journal: Head Neck Date: 2013-10-26 Impact factor: 3.147
Authors: Wen Jiang; Paul D Chamberlain; Adam S Garden; Betty Y S Kim; Dominic Ma; Emily J Lo; Diana Bell; G Brandon Gunn; Clifton D Fuller; David I Rosenthal; Beth M Beadle; Steven J Frank; William H Morrison; Adel K El-Naggar; Bonnie S Glisson; Erich M Sturgis; Jack Phan Journal: Head Neck Date: 2015-11-11 Impact factor: 3.147
Authors: Snjezana Dogan; Matthew L Hedberg; Robert L Ferris; Tanya J Rath; Adel M Assaad; Simion I Chiosea Journal: Head Neck Date: 2013-06-18 Impact factor: 3.147